Form 4: TMCI Officer's Routine Stock Disposition for Tax

Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, reported a disposition of 208 common shares for tax withholding purposes.

Summary

• Sean F. Scanlan, Chief Innovation Officer of Treace Medical Concepts, Inc. (TMCI), reported a transaction on October 24, 2025.
• The transaction involved the disposition of 208 shares of common stock.
• This disposition was coded 'F', indicating it was to satisfy tax withholding obligations.
• The price per share for this disposition was $0.
• Following this transaction, Mr. Scanlan beneficially owns 373,599 shares of common stock, which includes 283,948 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding purposes, which is neither inherently positive nor negative for the company's fundamentals or future prospects.

Future Outlook

No forward-looking statements or guidance are provided in this routine insider transaction report.

Industry Context

This is a routine insider transaction for tax withholding purposes and does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary disposition of shares by an insider to cover tax withholding obligations. Such transactions are common and do not typically reflect a change in management's outlook or the company's fundamentals, thus providing no new basis for a change in investment recommendation.

Keywords

Treace Medical Concepts, TMCI, Sean Scanlan, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Chief Innovation Officer, Restricted Stock Units